SISÄPIIRITIETO: Martela on saanut Isku Inspira Oy:lta vaatimuksen ylimääräisen yhtiökokouksen koollekutsumiseksi käsittelemään erityisen tarkastuksen toimittamista

Martela received a 10.37%-shareholder request from Isku Inspira Oy to convene an extraordinary meeting on a potential special audit covering 17 matters, including liquidity, financing needs, financial reporting, insider-information handling, related-party transactions and its proposed directed share issue. The request challenges the justification, pricing and anchor-investor selection for the September 8 capital raise, while Martela maintains that the financing is necessary to strengthen working capital, improve its capital structure and safeguard business continuity. The board will review the request but said the September 29 extraordinary meeting and proposed share issue cannot be delayed.

Analysis

MARAS now carries a two-layer discount: a near-term financing overhang and a governance-process risk premium. The key valuation issue is not the cost of a possible review itself, but whether the equity raise is perceived as being priced under distress; that would raise the required return for future capital and make any operational turnaround less valuable to existing holders. If working-capital release has supported cash generation more than underlying earnings, the market will focus on cash conversion and covenant headroom rather than reported profitability at the next results update.

The 29 September vote is the immediate binary catalyst. Approval removes the most acute continuity risk but likely crystallizes dilution; rejection or a materially delayed implementation creates a sharper downside because suppliers, customers and lenders may reassess counterparty risk before any formal liquidity event occurs. The competing-shareholder angle can also make this more than a one-off governance dispute: management distraction and disclosure scrutiny may impair tender conversion and customer retention in a cyclical office-furnishings market over the next 6-18 months.

Consensus may overstate the probability that a special review itself produces a financial liability. The more investable question is whether the eventual financing terms demonstrate independent price discovery and sufficient runway. A transparent, broadly accessible raise at a modest discount could remove the governance overhang and create a relief rally, but it would not validate a long thesis absent evidence that operating cash flow remains positive after normalized working-capital movements.

Key Decisions for Investors

• Maintain an underweight/avoid stance in MARAS through the 29 September meeting; the unfavorable asymmetry is dilution on approval versus potential liquidity repricing on rejection or delay. Reassess only after final subscription price, gross proceeds and post-raise liquidity runway are disclosed.
• For holders, reduce exposure into the vote rather than hedge with options: MARAS liquidity is likely insufficient for efficient listed-option protection. Treat any post-vote rally as sellable unless the issue discount is limited and management quantifies covenant headroom plus cash flow excluding working-capital release.
• Set a 1-3 month alert for H2 guidance revision, lender covenant amendments or evidence of extended supplier-payment terms. Any of these would falsify a benign-financing outcome and warrants further downside positioning; conversely, stable guidance and normalized cash conversion would be the first evidence against the distress thesis.
• Do not short aggressively solely on the review request. A review is unlikely to determine value on the relevant trading horizon; a disclosed fully funded balance sheet and credible third-party anchor demand could trigger a sharp technical rebound from depressed small-cap liquidity.